Concepedia

Sarah Eyde

SE

Statistics

Publications

2

Citations

239

H-Index

2

Active since

2023

Affiliations

Velocity Clinical Research (United States)(Current)

Eli Lilly (United States)

Sarah Eyde is an author at Velocity Clinical Research (United States) specializing in oral antidiabetic agents, diabetes management, and diabetes control.

Publications per year

2023–2025

2

Publications

2

Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study

Juan P. Frías, Stanley H. Hsia, Sarah Eyde et al. · The Lancet · 2023 · 159 citations

, , +11

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes

Julio Rosenstock, Stanley H. Hsia, Luis Nevárez Ruiz et al. · New England Journal of Medicine · 2025 · 80 citations

, , +17

1–2 of 2